Seth Pollack, MD,Fred Hutchinson Cancer Research Center
Recipient of the: Bud Lawall Memorial Research Award
Abstract: Synovial Sarcoma is a soft tissue sarcoma subtype with poor outcomes in the advanced setting. Although it is immunologically “cold,” it generally expresses the highly immunogenic protein NY-ESO-1. Although NY-ESO-1 has... Read More
Marc Ladanyi, MD,Memorial Sloan-Kettering Cancer Center
Recipient of the: Catherine Malatesta Memorial Research Award
Abstract: Loss of function mutations of STAG2 occur in 10-15% of Ewing sarcoma (ES) patients. This is clinically significant, as loss of STAG2 is associated with poor clinical outcomes. STAG2 encodes a protein that is central to the... Read More
Robert Schnepp, MD, PhD,Emory University - Winship Cancer Institute
Recipient of the: Derek G. Schnapp Memorial Research Award
Abstract: Despite significant efforts within oncology, effective therapies for alveolar rhabdomyosarcoma (ARMS) remain unrealized. Patients with ARMS are treated with intensive multimodal therapy, but outcomes still remain unaccepta... Read More
Anusha Kalbasi, MD,University of California, Los Angeles
Recipient of the: Jay Vernon Jackson Memorial Research Award
Abstract: The vast majority of patients with soft tissue sarcoma present with localized disease, yet nearly half of these patients develop incurable distant metastases. Chemotherapy has been marginally effective in reducing the rate... Read More
Maria Paola Paronetto, PhD,IRCCS Santa Lucia Foundation
Recipient of the: Pittsburgh Cure Sarcoma Research Award
Abstract: Ewing Sarcomas (ES) are biologically aggressive tumors of bone and soft tissues, characterized by in frame chromosomal translocation leading to the expression of the EWS-FLI1 oncogene. They affect mainly children and adole... Read More
Recipient of the: Race to Cure Sarcoma Research Award
Abstract: Targeting chromatin-remodeling enzymes holds great promise for treating soft tissue sarcomas (STS) since 1) the key oncogenic drivers in many sarcomas are translocation-derived chimeric transcription factors whose activiti... Read More
Matthew Hemming, MD, PhD,Dana-Farber Cancer Institute
Recipient of the: Race to Cure Sarcoma Research Award
Abstract: Sarcomas are uncommon and poorly understood malignancies of mesenchymal tissues. Their histologic diversity and diagnostic complexity bring tremendous challenge to optimal clinical management. The lack of understanding of ... Read More
Charles Keller III, MD,Children's Cancer Therapy Development Institute
Recipient of the: Race to Cure Sarcoma Research Award
Abstract: The Plexin-Semaphorin pathway is previously unexplored as a target in sarcomas but may play a central role in the progression of the soft tissue sarcoma, rhabdomyosarcoma. Rhabdomyosarcoma is the most common soft tissue sa... Read More
Nancy DeMore, MD,Medical University of South Carolina
Recipient of the: STL Cure Sarcoma Research Award
Abstract: Sarcomas are a heterogeneous group of malignancies with a 50% mortality at 5 years across all subtypes and stages. The 5 year survival for patients with metastatic disease is only 15%.The results from chemotherapeutic agen... Read More
Brian Van Tine, MD, PhD,Washington University in St. Louis
Recipient of the: Sarcoma Foundation of America Research Award
Abstract: Sarcomas are a group of over 100 types of tumors of mesenchymal origin that can be divided into soft tissue sarcomas (STS) and bone sarcomas. The most common agents used to treat all sarcomas are anthracyclines, such as do... Read More
